Laddar...
The future of treatment for patients with relapsed/refractory multiple myeloma: The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma
The ubiquitin-proteasome pathway was first validated as a target for cancer therapy with the demonstration of the activity of the boronic acid proteasome inhibitor bortezomib against relapsed and relapsed/refractory multiple myeloma. Another generation of proteasome inhibitors is now entering the cl...
Sparad:
| Huvudupphovsman: | |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4163602/ https://ncbi.nlm.nih.gov/pubmed/25188482 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|